José Manuel Soria, PhD: Genomics & complex diseases director at Hospital Sant Pau, KOL in thrombosis | Hospital de la Santa Creu i Sant Pau; Alexandre Perera, PhD: Physicist & electronic engineer KOL in AI, director at CREB (UPC) | Universitat Politècnica de Catalunya; 1 exit (Iproteos, actual Accure therapeutics); Pol Cervera: Operations in Startups & marketing expert, CMO at different startups | Exheus
Competition Sponsor: EIT Health of the European Union
Awardee Year: 2022
41 million people a year die from chronic disorders worldwide (obesity, diabetes, heart disease). The adoption of a sedentary lifestyle is driving obesity and related chronic disorders, and the WHO estimates that prevalence will increase by 57% by 2020.
Advanced diagnostic tools, such as genetic (DNA-based) testing, are ineffective in addressing these problems, as they only suggest the likelihood of developing a disease, but these disorders have less than a 20% predetermined genetic origin. Furthermore, they cannot monitor gene expression status or improvements made due to changes in diet, exercise, and medical plans, so they cannot follow an individual’s trajectory to provide tailored solutions.
No other diagnostic tool in existence today can support customized treatment and recommendations to patients with the high level of personalization expected to drive adherence that Exheus provides.
Physicians have time constraints and there are few tools to help them enroll their patients in lifestyle and anti-aging programs.
That’s why Exheus has created a unique health intelligence report that analyzes the expression levels of all 22,000 genes in the genome using RNA sequencing and AI. Exheus makes an accurate prediction of a person’s level of risk to a given treatment through gene expression analysis and AI-aided data processing. They offer the most personalized tool currently available on the market for treatment monitoring and chronic disease prevention.
To learn more about this proposal, email email@example.com.